The Yin and Yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff memorial lecture

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 7, 1996, Pages 831-842

  Navab, Mohamad ^d   Berliner, Judith A ^a   Watson, Andrew D ^d   Hama, Susan Y ^d   Territo, Mary C ^d   Lusis, Aldons J ^b   Shih, Diana M ^b   Van Lenten, Brian J ^d   Frank, Joy S ^a   Demer, Linda L ^a   Edwards, Peter A ^a   Fogelman, Alan M ^c  

^a School of Medicine

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

inflammatory reaction; lipid oxide

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ACUTE PHASE RESPONSE; ARTERY WALL; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CHINESE MEDICINE; ENZYME REGULATION; GENETIC REGULATION; HUMAN; INFLAMMATION; LIPID OXIDATION; OXIDATION; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; REVIEW;

EID: 8944258922     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.7.831     Document Type: Review

References (108)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
2. Young SG, Parthasarathy S. Why are low density lipoproteins atherogenic? West J Med. 1994;160:153-164.
3. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, I: focal increases in arterial LDL concentrations precede development of fatty streak lesions. Arteriosclerosis. 1989;9:895-907.
4. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, II: selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-913.
5. Kruth HS. Subendothelial accumulation of unesterified cholesterol: an early event in the atherosclerotic lesion development. Atherosclerosis. 1985;57:337-341.
6. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986;123:1109-1125.
7. Frank JS, Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J Lipid Res. 1989;30:967-978.
8. Nievelstein PFEM, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low-density lipoprotein: a deep-etch and immunolocalization study of rapidly frozen tissue. Arterioscler Thromb. 1991;11:1795-1805.
9. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb. 1994;14:1151-1161.
10. Camejo G, Olafsson F, Lopez P, Carisson P, Bondjers G. Identification of apoB-100 segments mediating the interaction of low-density lipoproteins with arterial proteoglycans. Arteriosclerosis. 1988;8:368-377.
11. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res. 1974;12:1-49.
12. Hoff HF, Heideman CL, Gaubatz JW, Gotto AM Jr, Erickson EE, Jackson RL. Quantification of apolipoprotein B in grossly normal human aorta. Circ Res. 1977;40:56-64.
13. Hoff HF, Heideman CL, Gotto AM Jr, Gaubatz JW. Apolipoprotein B retention in the grossly normal and atherosclerotic human aorta. Circ Res. 1977;41:684-690.
14. Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
15. Henricksen T, Mahoney EM, Steinberg D, Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low density lipoproteins, Proc Natl Acad Sci U S A. 1981;78:6499-6503.
16. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357-364.
17. Steinbrecher U, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;83:3883-3887.
18. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of LDL by human arterial smooth muscle cells. J Clin Invest. 1984;74:1890-1894.
19. Haberland ME, Fong D, Cheng L. Malondialdehyde altered protein occurs in atheroma of WHHL rabbits. Science. 1988;241:215-218.
20. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Sucher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. LDL undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1380.
21. Yla-Herttuala S, Palinski W, Rosenfeld S, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
22. Haberland ME, Steinbrecher UP. Modified low density lipoproteins: diversity and biologic relevance in atherosclerosis. In: Lusis AJ, Rotter JI, Sparkes RS, eds. Basel, Switzerland: S Karger; Molecular Genetics of Coronary Artery Disease. 1992:35-61.
23. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
24. Parthasarathy S. Modified Lipoproteins in the Pathogenesis of Atherosclerosis. Austin, Tex: RG Landes Co; 1994:91-119.
25. Parthasarathy S. Mechanism(s) of cell-mediated oxidation of low density lipoprotein. Free Radicals in the Environment, Medicine and Toxicology. Nohl H, Esterbauer H, Evans CR, eds. London, UK: Richelieu Press; 1994:163-179.
26. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
27. Chisolm GM. Antioxidants and atherosclerosis: a current assessment. Clin Cardiol. 1991;14:125-130.
28. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
29. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by β-carotene. Arterioscler Thromb. 1993;13:590-600.
30. Reaven PD. Mechanisms of atherosclerosis: role of LDL oxidation. Adv Exp Med Biol. 1994;366:113-128.
31. Jialal I, Grundy SM. Effect of combined supplementation with α-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation. 1993;88:2780-2786.
32. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
33. Vora DK, Fang ZT, Parhami F, Fogelman AM, Territo MC, Berliner JA. P-selectin induction by MM-LDL and its expression in human atherosclerotic lesions. Circulation. 1994;90(suppl I);I-83. Abstract.
34. Gushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified LDL induces monocyte chemotactic protein-1 in human endothelial and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
35. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature. 1990;344:254-257.
36. Schwartz D, Chaverri-Almada L, Berliner JA, Kirchgessener T, Quismorio DC, Fang ZT, Tekamp-Olson P, Lusis AJ, Fogelman AM, Territo MC. The role of a GRO homologue in monocyte adhesion to endothelium. J Clin Invest. 1994;94:1968-1973.
37. McEver RP. Leukocyte-endothelial interactions. Curr Opin Cell Biol. 1992;4:840-849.
38. Navab M, Hough GP, Stevenson LW, Drinkwater DC, Laks H, Fogelman AM, Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J Clin Invest. 1988;82:1853-1863.
39. Cushing SD, Fogelman AM. Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. Arterioscler Thromb. 1992;12:78-82.
40. Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, Fogelman AM. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest. 1991;87:2253-2257.
41. Neiken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127.
42. Bork RW, Svenson KL, Mehrabian M, Lusis AJ, Fogelman AM, Edwards PA. Mechanisms controlling competence gene expression in murine fibroblasts stimulated with minimally modified LDL. Arterioscler Thromb. 1992;12:800-806.
43. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.
44. i protein functions by minimally oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:2019-2024.
45. Pober JS, Slowik MR, De Luca LG, Ritchie AJ. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J Immunol. 1993;150:5114-5123.
46. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol. 1991;138:601-607.
47. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms - oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
48. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and endothelial cells in culture. Arteriosclerosis. 1979;32:213-229.
49. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest. 1995;95:2104-2110.
50. Navab M, Hama SY, Van Lenten BJ, Drinkwater DC, Laks H, Fogelman AM. A new anti-inflammatory compound, leumedin, inhibits modification of low density lipoprotein and the resulting monocyte transmigration into the subendothelial space of cocultures of human artery wall cells. J Clin Invest. 1993;91:1225-1230.
51. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
52. Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem. 1989;264:5331-5334.
53. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J Biol Chem. 1991;266:11095-11103.
54. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Physicians. 1993;105:44-63.
55. Deigner HP, Friedrich E, Sinn H, Dresel HA. Scavenging of lipid peroxidation products from oxidizing LDL by albumin alters the plasma half-life of a fraction of oxidized LDL particles. Free Radic Res Commun. 1992;16:239-246.
56. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
57. 2+ catalyzed oxidation of human low density lipoprotein. FEBS Lett. 1989;257:435-438.
58. Van Hinsbergh VW, Scheffer M, Havekes L, Kempen HJ. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta. 1986;878:49-64.
59. Dentan C, Lesnik M, Chapman J, Ninjio E. PAF-acether-degrading acetylyhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb. 1994;14:353-360.
60. Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G, Condorelli M, Chiariello M, Triggiani M. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest. 1994;93:2408-2416.
61. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
62. Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis? Chem Biol Interact. 1993;87:161-171.
63. Mackness MI, Walker CH, Carlson LA. Low 'A' esterase activity in serum of patients with fish eye disease. Clin Chem. 1987;35:587-588.
64. Mackness MI. Possible medical significance of human serum 'A' esterases. In: Reiner E, Aldridge WN, Hoskin FCG, eds. Enzymes Hydrolyzing Organophosphorus Compounds. Chichester, UK: Horwood Ltd; 1989:202-213.
65. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett. 1991;286:152-154.
66. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett. 1994;348:297-300.
67. 2α, in rabbit lung in situ. Am J Physiol. 1992;263:H660-H663.
68. Fukunaga M, Takahashi K, Badr KF. Vascular smooth muscle actions and receptor interactions of 8-iso-prostaglandin E2 and E2-isoprostane. Biochem Biophys Res Commun. 1993;195:507-515.
69. Heery JM, Kozak M, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Atherogenic effects of lipids from oxidized LDL. Circulation. 1993;88(suppl I):I-562. Abstract.
70. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes proinflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.
71. Pepys M, Baltz M. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
72. Cabana VH, Gewurz H, Siegel J. Interaction of very low density lipoproteins (VLDL) with rabbit C-reactive protein. J Immunol. 1982;128:2342-2348.
73. Benditt EP, Ericksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse high density lipoprotein. Proc Natl Acad Sci U S A. 1979;76:4092-4096.
74. Rienhoff HY Jr, Huang JH, Li XX, Liao WS. Molecular and cellular biology of serum amyloid A. Mol Biol Med. 1990;7:287-298.
75. Zahedi K, Gonnerman WA, De Beer FC, De Beer MC, Steel DM, Sipe JD, Whitehead AS. Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains. Inflammation. 1991;15:1-14.
76. Gutteridge JM, Stocks J. Ceruloplasmin: physiological and pathological perspectives. Crit Rev Clin Lab Sci. 1981;14:257-329.
77. Bustamante JB, Martin Mateo MC, Fernandez J, deQuiros B, Manchado OO. Zinc, copper and ceruloplasmin in arteriosclerosis. Biomedicine. 1976;25:244-245.
78. Ehrenwald E, Chisholm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest. 1994;93:1493-1501.
79. Lamb DJ, Leake DS. Acidic pH enables ceruloplasmin to catalyze the modification of low density lipoprotein. FEBS Lett. 1994;338:122-126.
80. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies denned by a lipoprotein-associated protein, K-45: identify of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
81. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250, 310-318.
82. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
83. Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation. 1994;89:503-505.
84. Henny AM, Wakely PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene in atherosclerotic plaques using in situ hybridization. Proc Natl Acad Sci U S A. 1991;88:8154-8158.
85. Galis ZS, Sukhova GFC, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
86. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
87. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest. 1993;91:2572-2579.
88. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:65-73.
89. Berliner JA, Territo M, Andalibi A, Navab M, Liao F, Cushing S, Imes S, Kim J, Van Lenten B, Lusis AJ, Fogelman AM. Modified lipoproteins and atherogenesis. In: Gotto AM Jr, ed. Cellular and Molecular Biology of Atherosclerosis. London, UK: Springer-Verlag; 1992:77-81.
90. Liao F, Andalibi A, Qiao J-H, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 1994;94:877-884.
91. Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci U S A. 1987;84:3763-3767.
92. Shih DM, Gu L, Hama S, Xia Y, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97:1630-1639.
93. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991;40:277-282.
94. Garin M-CB, Abbott C, Messmer S, Mackness M, Durrington D, Pometta D, James RW. Quantitation of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
95. Mackness MI, Durrington PN. Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet. 1995;346:856. Letter.
96. Ruiz J, Blanche H, James RW, Garin M-CB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995;346:869-872.
97. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
98. Humbert R, Adler DA, Disteche CM, Hassett C, Omiencinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
99. Barcroft J, Popjak GJ. Lipids in maternal and foetal blood plasma of sheep. J Physiol 1944;103:32-33.
100. Cornforth JW, Hunter GD, Popjak GJ. The biosynthesis of cholesterol from acetate. Arch Biochem Biophys. 1953;42:481-482.
101. Schambye P, Wood HG, Popjak GJ. Biological asymmetry of glycerol and formation of asymmetrically labeled glucose. J Biol Chem. 1954;206:875-882.
102. Cornforth JW, Popjak GJ, Youhotsky I. Absolute configuration of cholesterol. Nature. 1954;173:536-537.
103. Popjak GJ. Some uses of isotopes in research, with special reference to turnover studies. Practitioner. 1957;178:414-422.
104. Popjak GJ. Biosynthesis of cholesterol and related substances. Annu Rev Biochem. 1958;27:533-560.
105. Goodman DS, Popjak GJ. Synthesis of allyl pyrophosphates from mevalonate with liver enzymes and their relation to biosynthesis of squalene. Biochem J. 1960;74:35.
106. 14 incorporation in vitro. Rad Res. 1958;9:. Abstract.
107. Popjak GJ, Schroepfer G, Cornforth JW. Stereospecificity of hydrogen transfer from reduced nicotinamide-adenine dinucleotides to squalene. Biochem J. 1962;84:34.
108. Popjak GJ, Cornforth JW. Substrate stereochemistry in squalene biosynthesis: the first CIBA medal lecture. Biochem J. 1966;101:553-568.